izpis_h1_title_alt

Factor of time in dendritic cell (DC) maturation : short-term activation of DCs significantly improves type 1 cytokine production and T cell responses
ID Poženel, Primož (Avtor), ID Zajc, Kaja (Avtor), ID Švajger, Urban (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (3,43 MB)
MD5: 69F0E7A791E46A8047BF7B43E8A6B5A4
URLURL - Izvorni URL, za dostop obiščite https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05368-4 Povezava se odpre v novem oknu

Izvleček
Dendritic cells (DCs) have been intensively studied in correlation to tumor immunology and for the development DC-based cancer vaccines. Here, we present the significance of the temporal aspect of DC maturation for the most essential subsequent timepoint, namely at interaction with responding T cells or after CD40-Ligand restimulation. Mostly, DC maturation is still being achieved by activation processes which lasts 24 h to 48 h. We hypothesized this amount of time is excessive from a biological standpoint and could be the underlying cause for functional exhaustion. Indeed, shorter maturation periods resulted in extensive capacity of monocyte-derived DCs to produce inflammatory cytokines after re-stimulation with CD40-Ligand. This effect was most evident for the primary type 1 polarizing cytokine, IL-12p70. This capacity reached peak at 6 h and dropped sharply with longer exposure to initial maturation stimuli (up to 48 h). The 6 h maturation protocol reflected superiority in subsequent functionality tests. Namely, DCs displayed twice the allostimulatory capacity of 24 h- and 48 h-matured DCs. Similarly, type 1 T cell response measured by IFN-γ production was 3-fold higher when CD4$^+$ T cells had been stimulated with shortly matured DC and over 8-fold greater in case of CD8$^+$ T cells, compared to longer matured DCs. The extent of melanoma-specific CD8$^+$ cytotoxic T cell induction was also greater in case of 6 h DC maturation. The major limitation of the study is that it lacks in vivo evidence, which we aim to examine in the future. Our findings show an unexpectedly significant impact of temporal exposure to activation signals for subsequent DC functionality, which we believe can be readily integrated into existing knowledge on in vitro/ex vivo DC manipulation for various uses. We also believe this has important implications for DC vaccine design for future clinical trials.

Jezik:Angleški jezik
Ključne besede:dendritic cells, maturation, vaccines, cytotoxic T cells, cancer, anti-tumor responses
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:Str. 14 str.
Številčenje:Vol. 22, art. 541
PID:20.500.12556/RUL-158422 Povezava se odpre v novem oknu
UDK:615.371:616-006
ISSN pri članku:1479-5876
DOI:10.1186/s12967-024-05368-4 Povezava se odpre v novem oknu
COBISS.SI-ID:198061059 Povezava se odpre v novem oknu
Datum objave v RUL:10.06.2024
Število ogledov:298
Število prenosov:56
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Journal of translational medicine
Skrajšan naslov:J. transl. med.
Založnik:BioMed Central
ISSN:1479-5876
COBISS.SI-ID:513978393 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:dendritične celice, zorenje, citotoksične celice T, protitumorski odzivi, rak (medicina), cepiva

Projekti

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:J1-4417
Naslov:Razvoj novih nizkomolekularnih modulatorjev Tollu podobnih receptorjev 7 in 8 za imunoterapijo raka

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0371
Naslov:Človeške matične celice-napredno zdravljenje s celicami III

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj